Navigation Links
Regulus to Present at 32nd Annual J.P. Morgan Healthcare Conference
Date:1/7/2014

LA JOLLA, Calif., Jan. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 8:30 AM PST at the Westin St. Francis Hotel in San Francisco, CA.

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com. A replay of each webcast will be archived on the Company's website following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. Regulus is also developing RG-101, a GalN
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regulus to Present at 12th Annual Needham Healthcare Conference
2. Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
3. Regulus to Present at the Lazard Capital Markets Healthcare Conference
4. Regulus Files Registration Statement for Proposed Initial Public Offering
5. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
6. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 16TH ANNUAL NEEDHAM GROWTH CONFERENCE
8. Scioderm to Present at 32nd Annual J.P. Morgan Healthcare Conference
9. GlySure CEO to Present CE Mark Trial Results at OneMedForum 2014
10. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
11. PAREXEL International To Present At JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... CLEVELAND, Jan. 28, 2011 Arteriocyte®, a leading ... Ohio and Hopkinton, Massachusetts that develops proprietary stem ... approval from the Food and Drug Administration (FDA) ... its Magellan MAR01™ technology in the treatment of ...
... Reportlinker.com announces that a new ... its catalogue: ... Probes and Biochips -- New Product ... for Instrument and Reagent Suppliers ...
... Calif. and HOPKINTON, Mass., Jan. 27, 2011 ... (Nasdaq: CALP ) today announced a ... for next generation sequencing sample preparation on Caliper,s ... researchers to leverage NuGEN,s Ovation® and Encore™ reagent ...
Cached Biology Technology:Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 2Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 3Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 3
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Soil is the most species-rich microbial ecosystem ... certain species, give them access to the root and so ... then benefit in a variety of ways. To achieve this, ... of these bacteria are friends and which foes. Researchers from ...
... reported details of how certain drugs can precisely target ... replication. Since all strains of the virus require the ... drugs that can effectively treat new strains of the ... When new strains of influenza emerge, it can ...
... Results from a study conducted at Georgia State University ... intestines and the immune system, kicked off by another type ... disease. The study suggests that the "fight" continues after ... to Andrew Gewirtz, professor of biology at the GSU Center ...
Cached Biology News:Bacterial community inside the plant root 2Bacterial community inside the plant root 3Target for potent first-strike influenza drugs identified 2Target for potent first-strike influenza drugs identified 3Target for potent first-strike influenza drugs identified 4
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
... Immunogen: Recombinant protein ... region of human ubiquilin. ... the human ubiquilin protein. ... control: 293 cells). ...
...
Biology Products: